Brand Name(s): Glucotrol
CAS nº: 29094-61-9
(glip ih zide)

About Glipizide

This new site is dedicated exclusively to glipizide, the generic name for the more commonly-known medication Glucotrol®.

This reference portal provides you with the most extensive product information and up-to-date resources regarding this medication, including related news articles, medical studies, an image library and all the necessary information on dosage and side effects.

Whether you are an average consumers or pharma industry professionals, you can now find out everything you need to know about glipizide, as well as take part in our open discussion forum by sharing your own knowledge and experiences with people who are using this medication.

This unique site will also provide you with inside industry news on which companies or organizations are playing an important part in its research, development, production and promotion. It is your one-stop site for a total glipizide experience! 

Why is this medication prescribed?

Glipizide is used to treat type 2 (noninsulin-dependent) diabetes (formerly 'adult-onset'), particularly in people whose diabetes cannot be controlled by diet alone.

Glipizide lowers blood sugar by stimulating the pancreas to secrete insulin and helping the body use insulin efficiently. The pancreas must be capable of producing insulin for this medication to work.

However, glipizide is not used to treat type 1 (insulin-dependent) diabetes (formerly 'juvenile-onset').

See more Product Info

Latest News

Actavis Launches Glipizide ER Tablets in the U.S.

Actavis Group, the international generic pharmaceuticals company, today announced that Actavis...

[more]

Caraco Granted FDA Approval For Generic Anti-Diabetic Drug Glucotrol

On Wednesday, Caraco Pharmaceutical Laboratories Ltd., a provider of generic and private-label...

[more]

Diabetes pills lower blood sugar, weight too

Washington - Two experimental pills seem to help older diabetes drugs lower patients' blood sugar,...

[more]

New Oral Antidiabetic Agent May Offer Treatment Advantage for People with Type 2 Diabetes

Approximately 50 percent of the 17 million Americans who have been diagnosed with type 2 diabetes...

[more]

Drug stocks up; Merck gains on diabetes drug news

BOSTON (MarketWatch) -- Drug stocks finished the day in the red Tuesday, despite gains by Merck...

[more]

This site is intended solely for U.S. audiences; products described here may be subject to different medical and/or regulatory requirements in other countries. This site is for educational purposes only; information contained within should not be used to diagnose or treat a health problem or disease. Please consult a licensed health care provider regarding your medical condition.The products mentioned are trademarks of their respective owners.